Rhizen receives USFDA orphan drug designation for cancer drug
The US Food and Drug Administration (USFDA) has granted orphan drug designation for Tenalisib (RP6530) for the treatment of patients with peripheral T-cell lymphoma (PTCL), Alembic Pharmaceuticals said in a BSE filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 22, 2021 Category: Pharmaceuticals Source Type: news

Moffitt researchers discover potential new drug target to treat cutaneous T cell lymphoma
(H. Lee Moffitt Cancer Center& Research Institute) In order to improve their understanding of how CTCL develops in hopes of developing new therapies, a team of Moffitt scientists conducted a series of studies. In an article published in The Journal of Clinical Investigation, they demonstrate that decreased expression of the protein SATB1 contributes to CTCL development and that drugs that cause SATB1 to become re-expressed may be potential treatment options for this disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 21, 2020 Category: International Medicine & Public Health Source Type: news

PET useful modality in patients with lymphomas
PET imaging can permit more accurate staging in lymphomas, guide treatment,...Read more on AuntMinnie.comRelated Reading: PET/CT pinpoints Hodgkin's lymphoma treatment response PET rules out need for radiotherapy in lymphoma patients Routine PET field-of-view enough for pediatric lymphoma FDG-PET/CT fails for peripheral T-cell lymphoma outcomes PET obviates toxic chemo for some Hodgkin's patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 16, 2020 Category: Radiology Source Type: news

Allogeneic Transplant: Durable Remissions in T-Cell Lymphomas Allogeneic Transplant: Durable Remissions in T-Cell Lymphomas
Five-year progression-free survival approached 40% and 5-year overall survival was over 50% in the study. Treatment-related mortality ranged from about 8% to 24%, depending on the donor type.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 8, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Duvelisib Response Rate'Exciting' in Patients With r/r PTCL Duvelisib Response Rate'Exciting' in Patients With r/r PTCL
Duvelisib is demonstrating encouraging activity and manageable toxicities among patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) in a phase 2 trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 8, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

SIMPONI ARIA ® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glo...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Source Type: news

Extracoporeal photophoresis cost effective in cutaneous T-cell lymphoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 31, 2020 Category: Drugs & Pharmacology Source Type: news

Continued Treatment with SGX301 in Patients with CTCL Increases Response Rates
SGX301 is being evaluated for the treatment of patients with early-stage cutaneous T-cell lymphoma in the pivotal phase III FLASH study, which demonstrated that continued treatment twice weekly for 12 weeks increased the positive response rate. (Source: CancerNetwork)
Source: CancerNetwork - May 10, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma
SGX301 treatment response continues to demonstrate highly statistically significant improvement after 12 weeks of therapy Response rate in patients receiving a total of 12 weeks treatment increased two and a half-fold Reinforces positive SGX301 prima... Biopharmaceuticals, Oncology Soligenix, synthetic hypericin, cutaneous T-cell lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 30, 2020 Category: Pharmaceuticals Source Type: news

Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA ® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
HORSHAM, PA, April 24, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA® (golimumab) for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA), in patients two years of age and older in combination with methotrexate. If approved for these indications, SIMPONI ARIA would be the first anti-tumor necrosis factor (TNF)-alpha biologic agent administered by intravenous infusion av...
Source: Johnson and Johnson - April 24, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA Grants Fast Track Designation to Tipifarnib to Treat Lymphoma
Kura Oncology ’s leading drug candidate, tipifarnib, was granted fast track designation by the FDA to treat adults of T-cell lymphomas. (Source: CancerNetwork)
Source: CancerNetwork - March 3, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Old weapon, new target: Dasatinib against angioimmunoblastic T-cell lymphoma
(University of Tsukuba) Researchers from the University of Tsukuba have shown by in vivo experimentation on a mouse model that angioimmunoblastic T-cell lymphoma is highly dependent on T-Cell Receptor Signaling. Further trials also suggest that dasatinib, by targeting the TCR pathway, improved outcomes in both the mouse model and in a clinical trial of five patients who relapsed or were refractory to conventional therapy and therefore showed promise as a candidate drug for AITL treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 28, 2020 Category: International Medicine & Public Health Source Type: news

Discovery could lead to new treatment for rare blood disease
(University of Alberta Faculty of Medicine& Dentistry) A new study shows cancer cells found in the lesions on the skin of cutaneous T-cell lymphoma patients originate from the blood, not the skin as was believed. The protocol to treat the disease was to eliminate the cancer cells from the skin. Based on the findings, researchers believe it would be more effective to treat the malignant clones in the blood rather than waiting until the cells reach the skin and present as lesions. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 27, 2020 Category: Cancer & Oncology Source Type: news

Study Halted;'Hyperprogression' Seen With Nivolumab for R/R PTCL Study Halted;'Hyperprogression' Seen With Nivolumab for R/R PTCL
A phase 2 study suggests the checkpoint inhibitor is not the hoped-for salvage treatment in relapsed or refractory peripheral T-cell lymphoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 9, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

NUS researchers discover enzyme's role in 'natural killer T cell lymphoma'
(National University of Singapore) Researchers from the Cancer Science Institute of Singapore uncovered an enzyme which could serve as a potential biomarker for 'natural killer T cell lymphoma' and could lead to new targeting routes for treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 7, 2019 Category: Cancer & Oncology Source Type: news

Same Amazon.com that banned cancer cure documentaries now all in with Big Pharma's toxic cancer "treatments" via its new "Go Gold" astroturfing campaign
(Natural News) Jeff Bezos has launched a new propaganda campaign called “Amazon Goes Gold” that blatantly pushes the Big Pharma lie that chemotherapy is some kind of universal cure for childhood cancer. Exploiting the heartbreaking story of a Texas girl who underwent chemo for stage 4 non-Hodgkin’s T-cell Lymphoma, The Amazon blog makes the suggestion... (Source: NaturalNews.com)
Source: NaturalNews.com - September 15, 2019 Category: Consumer Health News Source Type: news

Cancer Victim: Monsanto Is Liable Due To 'Wrongful Conduct' Regarding Glyphosate
MINNEAPOLIS - A cancer victim on Aug. 14 sued Monsanto Co. in Minnesota federal court, contending that exposure to glyphosate, the active ingredient in the company's herbicide Roundup, caused his T-cell lymphoma and that Monsanto is liable for "negligent and wrongful conduct" associated with the manufacture and distribution of the chemical (Clifford McCord v. Monsanto Company, No. 19-2252, D. Minn.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - August 21, 2019 Category: Medical Law Source Type: news

Most diabetes patients unprepared for FDG-PET/CT scans
Many nuclear medicine practices are neglecting to tell patients with diabetes...Read more on AuntMinnie.comRelated Reading: FDG-PET/CT aids in melanoma treatment assessment FDG-PET/CT fails for peripheral T-cell lymphoma outcomes FDG-PET/CT helps stage men with breast cancer, too Prescan tutorial eases patient concerns about PET/CT PET technique could aid diabetic therapy monitoring (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 11, 2019 Category: Radiology Source Type: news

Most diabetic patients unprepared for FDG-PET/CT scans
Many nuclear medicine practices are neglecting to tell diabetic patients that...Read more on AuntMinnie.comRelated Reading: FDG-PET/CT aids in melanoma treatment assessment FDG-PET/CT fails for peripheral T-cell lymphoma outcomes FDG-PET/CT helps stage men with breast cancer, too Prescan tutorial eases patient concerns about PET/CT PET technique could aid diabetic therapy monitoring (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 10, 2019 Category: Radiology Source Type: news

HSCT in Advanced Stage Mycosis Fungoides and Sezary Syndrome HSCT in Advanced Stage Mycosis Fungoides and Sezary Syndrome
Is HSCT potentially curative for cutaneous T-cell lymphoma?Chinese Clinical Oncology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 29, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology Journal Article Source Type: news

City of Hope awarded $7.5 million to develop better treatment for a rare, incurable cancer
(City of Hope) City of Hope recently received $7.5 million to study a rare type of blood cancer that affects the skin: cutaneous T cell lymphoma. The NCI awarded $6.3 million over five years to City of Hope's Steven Rosen, M.D., and Christiane Querfeld, M.D., Ph.D., so they can develop improved therapies for the disfiguring, incurable cancer that affects about 3,000 new individuals per year. LLS gave the pair two grants totaling $1.2 million over three years. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 21, 2019 Category: International Medicine & Public Health Source Type: news

2 new PET tracers may best FDG in cancer imaging
Cancer detection could receive a boost from two new radiotracers that have...Read more on AuntMinnie.comRelated Reading: Later PET/CT follow-up helps for oropharyngeal cancer Ga-68 PSMA-11 PET/MRI improves prostate cancer detection New PET tracer could aid melanoma detection FDG-PET/CT fails for peripheral T-cell lymphoma outcomes PET/CT predicts success of rad therapy for spinal mets (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 14, 2019 Category: Radiology Source Type: news

Later PET/CT follow-up helps for oropharyngeal cancer
Using PET/CT for follow-up at a later interval than what's recommended by existing...Read more on AuntMinnie.comRelated Reading: FDG-PET/CT aids in melanoma treatment assessment CT lung screening can catch recurring head, neck cancer ASTRO: Blood test confirms HPV-related cancer remission FDG-PET/CT fails for peripheral T-cell lymphoma outcomes FDG-PET/CT helps stage men with breast cancer, too (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 11, 2019 Category: Radiology Source Type: news

Book Review: Living Light:  The Art of Using Light for Health & Happiness
While it’s hard not to notice the brilliant display of colors set off by a sunset over the water, we seldom consider the biological, or even psychological, benefits of light. “It is my belief that good quality light in our daily lives is far more important than we might think,” writes Karl Ryberg. In his new book, Living Light: The Art of Using Light For Health And Happiness, Ryberg brings us his life’s work — studying the obvious and not so obvious ways in which light affects us and how we can use light in our lives not only function better, but feel better. Light, we know, plays an important...
Source: Psych Central - March 10, 2019 Category: Psychiatry Authors: Claire Nana Tags: Book Reviews Disorders General Habits Psychology Seasonal Affective Disorder Self-Help Treatment artificial light Light therapy Living Light natural light Ryberg SAD Source Type: news

Antibody-Based Therapies for Cutaneous T-Cell Lymphoma Antibody-Based Therapies for Cutaneous T-Cell Lymphoma
Monoclonal antibody therapies, such as alemtuzumab, brentuximab vedotin, and mogamulizumab, are showing promise for previously relapsed and refractory CTCL.American Journal of Clinical Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 8, 2019 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

FDG-PET/CT aids in melanoma treatment assessment
Researchers have developed a new FDG-PET/CT-based approach to better monitor...Read more on AuntMinnie.comRelated Reading: New PET tracer could aid melanoma detection FDG-PET/CT fails for peripheral T-cell lymphoma outcomes PET/CT predicts success of rad therapy for spinal mets FDG-PET/CT helps stage men with breast cancer, too PET/CT makes case for directing cervical cancer treatment (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 7, 2019 Category: Radiology Source Type: news

Caution urged for breast MRI evaluation of lymph nodes
VIENNA - How well can MRI diagnose axillary lymph node metastases in patients...Read more on AuntMinnie.comRelated Reading: AI may predict lymph node metastasis in gastric cancer FDG-PET/CT fails for peripheral T-cell lymphoma outcomes PET/MRI falls short in lymph node metastases analysis Midlevel image features help CAD find lymph nodes PET/MRI tops DWI-MRI for head/neck lymph node metastases (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 28, 2019 Category: Radiology Source Type: news

Aurora A kinase Inhibitor vs Standard Treatment for PTCL
Is Aurora A kinase inhibitor alisertib superior to standard treatment protocol for peripheral T-cell lymphoma? (Source: CancerNetwork)
Source: CancerNetwork - February 18, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Autologous Stem Cell Transplant May Aid Some With Nodal PTCL
WEDNESDAY, Feb. 13, 2019 -- Autologous stem cell transplantation (ASCT) may be beneficial for some patients with nodal peripheral T-cell lymphoma (PTCL) in the first complete remission (CR1), according to a study published online Jan. 29 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 13, 2019 Category: Pharmaceuticals Source Type: news

Breast Implant Link to Rare T-Cell Lymphoma an Ongoing Concern Breast Implant Link to Rare T-Cell Lymphoma an Ongoing Concern
Most confirmed cases have been associated with textured implants, which have been more popular in Europe than in the United States.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 6, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

$8 million grant pairs Wake Forest Baptist Health with 'Dream Team' fighting lymphoma
Wake Forest Baptist Health Comprehensive Cancer Center is one of four health systems from across the country to share in an $8 million grant from the American Association for Cancer Research.   The money is to be used to put together a “dream team” of doctors and researchers to develop therapies to better treat T-cell lymphoma, a rare cancer of the blood and immune system. T-cell lymphomas account for less than 15 percent of non-Hodgkin lymphomas in the U.S., according to the Amer ican Cancer… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - January 29, 2019 Category: Health Management Authors: John Joyce Source Type: news

Stand Up To Cancer dream team tackles t-cell lymphoma, focused on CAR-based strategies
(Stand Up To Cancer) A new $8 million SU2C Dream Team is focused on therapies for T-cell lymphoma using CARs to trigger the immune system to attack and destroy cancerous cells led by Helen Heslop, M.D., Baylor College of Medicine, co-led by Gianpietro Dotti, M.D., UNC Chapel Hill: seeking to develop " off the shelf " CAR cells improving availability& lowering cost; identifying biomarkers to track therapy effectiveness; evaluating a novel small molecule which shows potential as a cytoreductive regimen. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 28, 2019 Category: Cancer & Oncology Source Type: news

New PET tracer could aid melanoma detection
A new PET tracer designed to target melanin pigment could improve the detection...Read more on AuntMinnie.comRelated Reading: FDG-PET/CT fails for peripheral T-cell lymphoma outcomes PET/CT makes case for directing cervical cancer treatment FLT-PET points toward survival for glioblastoma patients Extremity PET/CT scans unnecessary for melanoma patients FDG-PET/CT foretells melanoma therapy response (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 17, 2019 Category: Radiology Source Type: news

Brentuximab Vedotin and Chemotherapy Effective in Peripheral T-cell Lymphoma Brentuximab Vedotin and Chemotherapy Effective in Peripheral T-cell Lymphoma
Brentuximab vedotin (Adcetris, Seattle Genetics) in combination with chemotherapy is significantly more effective than chemotherapy alone in patients with CD30-positive peripheral T-cell lymphomas, according to the multinational phase 3 ECHELON-2 trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 17, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

The Long-Term Outlook for Mogamulizumab in Previously Treated Cutaneous T-Cell Lymphoma
The results of a follow-up analysis to the phase III  MAVORIC study were presented at the ASH 2018 Annual Meeting& Exposition. (Source: CancerNetwork)
Source: CancerNetwork - December 6, 2018 Category: Cancer & Oncology Authors: Traci DeVito Source Type: news

ASH: A + CHP Bests CHOP for Peripheral T - Cell Lymphoma
Median progression - free survival improved with A + CHP vs CHOP; similar incidence of adverse events (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 5, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Conference News, Source Type: news

ASH: A & #43;CHP Bests CHOP for Peripheral T-Cell Lymphoma
WEDNESDAY, Dec. 5, 2018 -- For patients with CD30-positive peripheral T-cell lymphoma, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) is superior to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 5, 2018 Category: Pharmaceuticals Source Type: news

DWI-MRI may be best for indeterminate lung nodules
Diffusion-weighted MRI (DWI-MRI) offers comparable or even superior diagnostic...Read more on AuntMinnie.comRelated Reading: MRI shows promise for lung cancer screening FDG-PET/CT fails for peripheral T-cell lymphoma outcomes FDG-PET/CT helps stage men with breast cancer, too PET/CT makes case for directing cervical cancer treatment (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 3, 2018 Category: Radiology Source Type: news

FDA Approves First-Line Tx for Peripheral T-Cell Lymphoma
MONDAY, Nov. 19, 2018 -- The U.S. Food and Drug Administration on Friday expanded approval for the use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with specific types of peripheral T-cell lymphoma... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 19, 2018 Category: Pharmaceuticals Source Type: news

FDA approves first-line treatment for peripheral T-cell lymphoma under new review pilot
The U.S. Food and Drug Administration expanded the approved use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma (PTCL). This is the first FDA approval for treatment of newly diagnosed PTCL, and the agency used a new review program to complete the approval more quickly. (Source: World Pharma News)
Source: World Pharma News - November 19, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Approves Adcetris (brentuximab vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 16, 2018-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced a new approval for Adcetris (brentuximab vedotin) in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone) from the U.S.... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 16, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Approves First-Line Adcetris for Peripheral T-Cell Lymphoma
(MedPage Today) -- Added to chemotherapy, drug delayed disease progression by over 2 years (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 16, 2018 Category: American Health Source Type: news

FDA approves first-line treatment for peripheral T-cell lymphoma under new review pilot
The FDA expanded the approved use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma (PTCL). This is the first FDA approval for treatment of newly diagnosed PTCL, and the agency used a new review program to complete the approval more quickly. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 16, 2018 Category: American Health Source Type: news

Robot arm assists with PET/CT-guided needle biopsies
By combining a robotic arm-assisted needle navigation system with PET/CT, researchers...Read more on AuntMinnie.comRelated Reading: FDG-PET/CT fails for peripheral T-cell lymphoma outcomes FDG-PET/CT helps stage men with breast cancer, too PET/CT key to NIH's tuberculosis research plan PET/CT makes case for directing cervical cancer treatment Can deep learning monitor lesions on F-18 NaF PET/CT? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 6, 2018 Category: Radiology Source Type: news

Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-cell Lymphoma
PRINCETON, N.J., Oct. 15, 2018 -- (Healthcare Sales & Marketing Network) -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where t... Biopharmaceuticals, Oncology Soligenix, hypericin, cutaneous T-cell lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 15, 2018 Category: Pharmaceuticals Source Type: news

FDG-PET/CT fails for peripheral T-cell lymphoma outcomes
Don't expect much help from FDG-PET/CT results in predicting progression-free...Read more on AuntMinnie.comRelated Reading: FDG-PET/CT helps stage men with breast cancer, too PET/CT key to NIH's tuberculosis research plan PET/CT makes case for directing cervical cancer treatment Prescan tutorial eases patient concerns about PET/CT Can deep learning monitor lesions on F-18 NaF PET/CT? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 5, 2018 Category: Radiology Source Type: news

Mogamulizumab Approved for Two Rare Types of Cutaneous T-cell Lymphoma
Mogamulizumab (Poteligeo) is indicated for  relapsed or refractory mycosis fungoides or Sézary syndrome following at least one prior systemic therapy. (Source: CancerNetwork)
Source: CancerNetwork - September 11, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice —PART 2: ENKTL, EATL, Indolent T-Cell LDP of the GI Tract, ATLL, and Hepatosplenic T-Cell Lymphoma
In Part 2 of this two-part series, this review covers extranodal natural killer/T-cell lymphoma, enteropathy-associated T-cell lymphoma, indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, adult T-cell leukemia/lymphoma, and hepatosplenic T-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - August 27, 2018 Category: Cancer & Oncology Authors: Natalia Pin Chuen Zing, MD, MSc, Thais Fischer, MD, Jasmine Zain, MD, Massimo Federico, MD, Steven T. Rosen, MD Source Type: news

PART 2: Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice —ENKTL, EATL, Indolent T-Cell LDP of the GI Tract, ATLL, and Hepatosplenic T-Cell Lymphoma
In Part 2 of this two-part series, this review covers extranodal natural killer/T-cell lymphoma, enteropathy-associated T-cell lymphoma, indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, adult T-cell leukemia/lymphoma, and hepatosplenic T-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - August 23, 2018 Category: Cancer & Oncology Authors: Natalia Pin Chuen Zing, MD, MSc, Thais Fischer, MD, Jasmine Zain, MD, Massimo Federico, MD, Steven T. Rosen, MD Source Type: news

Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice —PART 2: ENKTL, EATL, Indolent T-Cell LDP of the GI Tract, ATLL, and Hepatosplenic T-Cell Lymphoma
In Part 2 of this two-part series, this review covers extranodal natural killer/T-cell lymphoma, enteropathy-associated T-cell lymphoma, indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, adult T-cell leukemia/lymphoma, and hepatosplenic T-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2018 Category: Cancer & Oncology Authors: Natalia Pin Chuen Zing, MD, MSc, Thais Fischer, MD, Jasmine Zain, MD, Massimo Federico, MD, Steven T. Rosen, MD Source Type: news